[Enhancing factors in the cardiotoxicity of anthracyclines].
We have studied 60 pediatric patients with different neoplastic diseases, treated with anthracyclines. We have followed them clinically and echocardiographically to detect the cardiotoxicity due to anthracyclines and the enhanced factors promptly. We have detected a more important incidence of cardiomyopathy in patients with non-Hodgkin's lymphoma, osteosarcoma and neuroblastoma despite cumulative doses under 550 mg/m2 of anthracyclines. The 2 first groups were treated with high doses of cyclophosphamide and methotrexate, and neuroblastomas with melphalan. The anthracyclines cardiotoxicity is evaluated around 5% in patients treated with doses under 550 mg/m2, and is increased in case of previous or simultaneous aggressive therapy. Continued echocardiography enables a premature detection of cardiotoxicity in these high risk patients.
Sanz Manrique
N
N
Servicio de Oncología Pediátrica, Hospital Infantil Valle de Hebrón, Universidad Autónoma de Barcelona.
Valcarce Pérez
J
J
Broto Escapa
P
P
Escribano Subías
J
J
Casaldáliga Ferrer
J
J
Moraga Llop
F A
FA
Sánchez de Toledo Codina
J
J
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004357:Drug Synergism; D004452:Echocardiography; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D008727:Methotrexate
Factores coadyuvantes de la toxicidad cardiaca por antraciclínicos.